FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086663807> ?p ?o ?g. }

• W2086663807 endingPage "15" @default.
• W2086663807 startingPage "15" @default.
• W2086663807 abstract "An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease Carla EM HollakDepartment of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The NetherlandsAbstract: Gaucher disease is an inherited lysosomal storage disorder, characterized by deficient activity of glucocerebrosidase leading to storage of glucocerebroside in tissue macrophages. Type I disease, the most prevalent form, lacks central nervous system involvement but presents primarily with variable degrees of hepatosplenomegaly, cytopenia, and bone disease. Intravenous enzyme replacement therapy can reverse these manifestations. In addition to the two enzymes currently authorized for use, the newest enzyme, taliglucerase alfa, is at the late stages of clinical development. Taliglucerase alfa is a unique product, as it is the first plant cell–based recombinant enzyme therapy. This review considers the existing evidence for therapeutic efficacy of taliglucerase alfa in the treatment of the non-neuronopathic manifestations of Gaucher disease. Clinical studies encompass one phase I trial in healthy volunteers, one phase III trial, and preliminary results from both an extension study and a switch study. In the 9-month, randomized, double-blind phase III trial, treatment-naïve patients with type I Gaucher disease were treated with either 30 or 60 U/kg every 2 weeks. Dose-dependent improvements were achieved after 6 and 9 months of therapy, with reductions in spleen and liver volumes and improvements in hemoglobin levels. Platelet counts improved initially only in the higher-dose group, but preliminary results from the extension study also show significant increases in the lower-dose group. Bone marrow involvement, as assessed by magnetic resonance imaging, improved in almost all patients. Taliglucerase alfa has shown a good safety profile, with few patients experiencing hypersensitivity reactions and developing antibodies. An additional enzyme replacement therapy for Gaucher disease would enable the treatment of more patients and would provide backup for unexpected production problems. Furthermore, it is expected that this new treatment would reduce the costs of therapy. Taliglucerase alfa is a valuable new treatment modality for the non-neuronopathic manifestations of Gaucher disease.Keywords: lysosomal storage disorder, glucocerebrosidase deficiency, enzyme replacement therapy, plant-derived recombinant human glucocerebrosidase" @default.
• W2086663807 created "2016-06-24" @default.
• W2086663807 creator A5024669037 @default.
• W2086663807 date "2012-05-01" @default.
• W2086663807 modified "2023-10-16" @default.
• W2086663807 title "An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease" @default.
• W2086663807 cites W1831130622 @default.
• W2086663807 cites W1982815060 @default.
• W2086663807 cites W1988253322 @default.
• W2086663807 cites W2002571030 @default.
• W2086663807 cites W2016845221 @default.
• W2086663807 cites W2020887709 @default.
• W2086663807 cites W2033061415 @default.
• W2086663807 cites W2088638526 @default.
• W2086663807 cites W2102761052 @default.
• W2086663807 cites W2103986567 @default.
• W2086663807 cites W2115871259 @default.
• W2086663807 cites W2144456776 @default.
• W2086663807 cites W2145198531 @default.
• W2086663807 cites W2158778040 @default.
• W2086663807 cites W2322128806 @default.
• W2086663807 cites W2325696847 @default.
• W2086663807 cites W2334181337 @default.
• W2086663807 doi "https://doi.org/10.2147/ce.s20201" @default.
• W2086663807 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3363131" @default.
• W2086663807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22654679" @default.
• W2086663807 hasPublicationYear "2012" @default.
• W2086663807 type Work @default.
• W2086663807 sameAs 2086663807 @default.
• W2086663807 citedByCount "25" @default.
• W2086663807 countsByYear W20866638072012 @default.
• W2086663807 countsByYear W20866638072013 @default.
• W2086663807 countsByYear W20866638072014 @default.
• W2086663807 countsByYear W20866638072015 @default.
• W2086663807 countsByYear W20866638072016 @default.
• W2086663807 countsByYear W20866638072017 @default.
• W2086663807 countsByYear W20866638072018 @default.
• W2086663807 countsByYear W20866638072022 @default.
• W2086663807 crossrefType "journal-article" @default.
• W2086663807 hasAuthorship W2086663807A5024669037 @default.
• W2086663807 hasBestOaLocation W20866638071 @default.
• W2086663807 hasConcept C126322002 @default.
• W2086663807 hasConcept C2776723260 @default.
• W2086663807 hasConcept C2779134260 @default.
• W2086663807 hasConcept C2779440204 @default.
• W2086663807 hasConcept C2779969927 @default.
• W2086663807 hasConcept C2779994418 @default.
• W2086663807 hasConcept C2780007613 @default.
• W2086663807 hasConcept C2780366003 @default.
• W2086663807 hasConcept C2780674200 @default.
• W2086663807 hasConcept C535046627 @default.
• W2086663807 hasConcept C71924100 @default.
• W2086663807 hasConcept C90924648 @default.
• W2086663807 hasConceptScore W2086663807C126322002 @default.
• W2086663807 hasConceptScore W2086663807C2776723260 @default.
• W2086663807 hasConceptScore W2086663807C2779134260 @default.
• W2086663807 hasConceptScore W2086663807C2779440204 @default.
• W2086663807 hasConceptScore W2086663807C2779969927 @default.
• W2086663807 hasConceptScore W2086663807C2779994418 @default.
• W2086663807 hasConceptScore W2086663807C2780007613 @default.
• W2086663807 hasConceptScore W2086663807C2780366003 @default.
• W2086663807 hasConceptScore W2086663807C2780674200 @default.
• W2086663807 hasConceptScore W2086663807C535046627 @default.
• W2086663807 hasConceptScore W2086663807C71924100 @default.
• W2086663807 hasConceptScore W2086663807C90924648 @default.
• W2086663807 hasLocation W20866638071 @default.
• W2086663807 hasLocation W20866638072 @default.
• W2086663807 hasLocation W20866638073 @default.
• W2086663807 hasLocation W20866638074 @default.
• W2086663807 hasOpenAccess W2086663807 @default.
• W2086663807 hasPrimaryLocation W20866638071 @default.
• W2086663807 hasRelatedWork W1982567030 @default.
• W2086663807 hasRelatedWork W2042557135 @default.
• W2086663807 hasRelatedWork W2118170260 @default.
• W2086663807 hasRelatedWork W2281150386 @default.
• W2086663807 hasRelatedWork W2444093526 @default.
• W2086663807 hasRelatedWork W2891948505 @default.
• W2086663807 hasRelatedWork W2990639370 @default.
• W2086663807 hasRelatedWork W3185995161 @default.
• W2086663807 hasRelatedWork W2137855166 @default.
• W2086663807 hasRelatedWork W2496040907 @default.
• W2086663807 isParatext "false" @default.
• W2086663807 isRetracted "false" @default.
• W2086663807 magId "2086663807" @default.
• W2086663807 workType "article" @default.